FULCRUM THERAPEUTICS INC's ticker is FULC and the CUSIP is 359616109. A total of 56 filers reported holding FULCRUM THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $108,713 | +34.5% | 24,485 | 0.0% | 0.00% | – |
| Q2 2023 | $80,801 | -79.9% | 24,485 | -82.7% | 0.00% | – |
| Q1 2023 | $402,736 | -51.8% | 141,311 | +23.0% | 0.00% | – |
| Q4 2022 | $836,377 | +11.4% | 114,887 | +23.8% | 0.00% | – |
| Q3 2022 | $751,000 | +78.0% | 92,771 | +8.0% | 0.00% | – |
| Q2 2022 | $422,000 | -75.3% | 85,919 | +19.0% | 0.00% | -100.0% |
| Q1 2022 | $1,708,000 | +37.0% | 72,209 | +2.4% | 0.00% | – |
| Q4 2021 | $1,247,000 | -34.4% | 70,485 | +4.7% | 0.00% | -100.0% |
| Q3 2021 | $1,900,000 | +233.9% | 67,348 | +24.1% | 0.00% | – |
| Q2 2021 | $569,000 | +10.7% | 54,284 | +24.4% | 0.00% | – |
| Q1 2021 | $514,000 | +18.4% | 43,630 | +17.9% | 0.00% | – |
| Q4 2020 | $434,000 | +66.9% | 37,014 | +13.2% | 0.00% | – |
| Q3 2020 | $260,000 | -52.4% | 32,708 | +9.8% | 0.00% | – |
| Q2 2020 | $546,000 | +70.6% | 29,798 | +11.3% | 0.00% | – |
| Q1 2020 | $320,000 | – | 26,769 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP III, LLC | 3,962,202 | $19,415,000 | 7.94% |
| TRV GP IV, LLC | 2,343,154 | $11,481,000 | 7.55% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 949 | $193,741,000 | 2.02% |
| Logos Global Management LP | 1,950,000 | $9,555,000 | 1.75% |
| COWEN AND COMPANY, LLC | 2,385,885 | $11,691,000 | 1.13% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 3,355,624 | $16,443,000 | 0.62% |
| ACUTA CAPITAL PARTNERS, LLC | 200,000 | $980,000 | 0.55% |
| RTW INVESTMENTS, LP | 3,961,194 | $19,410,000 | 0.50% |
| Parkman Healthcare Partners LLC | 262,689 | $1,287,000 | 0.47% |
| Deep Track Capital, LP | 1,000,000 | $4,900,000 | 0.32% |